ArticleBMC microbiology2024
Molecular epidemiology of Mycoplasma pneumoniae pneumonia in children, Wuhan, 2020-2022.
Article in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 55 citations in OpenAlex.
- Epidemiological Characteristics and Clinical Impact of Macrolide-Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021-2025.The clinical respiratory journal · 2026Article
- Risk factors associated with pleural effusion in pediatric patients with severe Mycoplasma pneumonia.Medicine · 2026Observational
- Trends and outcomes ofMicrobiology spectrum · 2026Article
- Early clinical predictors of macrolide-resistant Mycoplasma pneumoniae pneumonia in hospitalized children during the 2024 outbreak in South Korea.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Utility of a Combined Diagnostic and Severity Scoring System Based on Complete Blood Count and Derived Immune-Inflammatory Indicators in Children With Mycoplasma pneumoniae Pneumonia.Journal of clinical laboratory analysis · 2026Article
- Routine admission biomarkers for identifying co-infection and stratifying severity in pediatric macrolide-resistantTranslational pediatrics · 2026Article
- Article
- High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.Clinical and experimental pediatrics · 2026Article
- Targeted next-generation sequencing reveals pathogen spectrum, drug resistance characteristics, and clinical determinants in children with community-acquired pneumonia.Translational pediatrics · 2026Article
- Knowledge, attitudes, and practices regarding mycoplasma pneumoniae pneumonia among family members of affected children.Scientific reports · 2026Article
- Correlation analysis of serum CHI3L1, HMGB1, and CD62E detection with the prognosis of Mycoplasma pneumoniae in children.Journal of medical biochemistry · 2026Article
- Unveiling metagenomic and metabolomic signatures in mild and severe pneumonia caused byMicrobial genomics · 2026Article
- Association between normalizedTranslational pediatrics · 2026Article
- Correlation analysis of FABP3, MCP-4, and CXCL9 levels and myocardial damage in patients with severe pneumonia.Journal of medical biochemistry · 2026Article
- Beyond Ribosomal Mutations: Identification ofMicroorganisms · 2026Article
- In Silico Design and Characterization of a Multi-Epitope Vaccine Candidate AgainstMicroorganisms · 2026Article
- Article
- Analysis of risk factors for the development of bronchiolitis obliterans in children with severeFrontiers in medicine · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMycoplasma pneumoniae (M. pneumoniae) is an important pathogen of community-acquired pneumonia in children. The factors contributing to the severity of illness caused by M. pneumoniae infection are still under investigation. We aimed to evaluate the sensitivity of common M. pneumoniae detection methods, as well as to analyze the clinical manifestations, genotypes, macrolide resistance, respiratory microenvironment, and their relationship with the severity of illness in children with M. pneumoniae pneumonia in Wuhan.
resultsAmong 1,259 clinical samples, 461 samples were positive for M. pneumoniae via quantitative polymerase chain reaction (qPCR). Furthermore, we found that while serological testing is not highly sensitive in detecting M. pneumoniae infection, but it may serve as an indicator for predicting severe cases. We successfully identified the adhesin P1 (P1) genotypes of 127 samples based on metagenomic and Sanger sequencing, with P1-type 1 (113/127, 88.98%) being the dominant genotype. No significant difference in pathogenicity was observed among different genotypes. The macrolide resistance rate of M. pneumoniae isolates was 96% (48/50) and all mutations were A2063G in domain V of 23S rRNA gene. There was no significant difference between the upper respiratory microbiome of patients with mild and severe symptoms.
conclusionsDuring the period of this study, the main circulating M. pneumoniae was P1-type 1, with a resistance rate of 96%. Key findings include the efficacy of qPCR in detecting M. pneumoniae, the potential of IgM titers exceeding 1:160 as indicators for illness severity, and the lack of a direct correlation between disease severity and genotypic characteristics or respiratory microenvironment. This study is the first to characterize the epidemic and genomic features of M. pneumoniae in Wuhan after the COVID-19 outbreak in 2020, which provides a scientific data basis for monitoring and infection prevention and control of M. pneumoniae in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.